Evidence map›Paper›PMID 30004410›Full record

ArticleVaccines2018

The Immunity Gap Challenge: Protection against a Recent Florida Clade 2 Equine Influenza Strain.

Romain Paillot, Dion Garrett, Maria R Lopez-Alvarez, Ihlan Birand, Fernando Montesso, Linda Horspool

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Hemagglutinin inhibition antibody responses to commercial equine influenza vaccines in vaccinated horses.The Canadian veterinary journal = La revue veterinaire canadienne · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Romain PaillotAnimal Health Trust, Lanwades Park, Kentford, Newmarket CB8 7UU, UK. romain.paillot@laboratoire-labeo.fr.
Dion GarrettAnimal Health Trust, Lanwades Park, Kentford, Newmarket CB8 7UU, UK. diongarrett013@gmail.com.ORCID 0000-0001-7350-2763
Maria R Lopez-AlvarezAnimal Health Trust, Lanwades Park, Kentford, Newmarket CB8 7UU, UK. MARIA.LOPEZ@aht.org.uk.ORCID 0000-0003-4207-0739
Ihlan BirandAnimal Health Trust, Lanwades Park, Kentford, Newmarket CB8 7UU, UK. ilhanbirand@hotmail.com.
Fernando MontessoAnimal Health Trust, Lanwades Park, Kentford, Newmarket CB8 7UU, UK. fmontesso66@gmail.com.
Linda HorspoolMSD Animal Health, 5830 AA Boxmeer, The Netherlands. linda.horspool@merck.com.
Animal Health Trust · GBMSD (Netherlands) · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination is one of the most effective tools for limiting the impact of equine influenza (EI). The humoral immunity established following a primary vaccination course can decrease significantly between the second (V2) and third immunisations (V3), leaving some horses insufficiently protected for several weeks. This so-called "immunity gap" poses a challenge to all EI vaccines. During this period, the EI infection of vaccinated animals may be followed by marked clinical signs and virus shedding. However, several EI vaccines have been shown to stimulate equine influenza virus (EIV)-specific cell-mediated immunity, which is likely to play a role in protection against EIV infection and/or mitigate the clinical and virological signs of EI. Reducing the interval between V2 and V3 has been shown to be counterproductive to longer-term immunity. Further research is needed to define and address the "immunity gap" in horses. This study aimed to measure the level of protection induced by a whole inactivated, ISCOMatrix adjuvanted, EI and tetanus vaccine (Equilis Prequenza-Te) when challenged during the immunity gap (i.e., immediately before the recommended boost immunisation, more than 5 months after V2) using infection with a recent heterologous Florida Clade 2 (FC2) equine influenza virus (EIV) strain. This vaccine was tested in a Welsh mountain pony model. A group of seven ponies was vaccinated twice, 4 weeks apart. The protective antibody response was measured and ponies were challenged, along with 5 unvaccinated control ponies, by experimental infection with the FC2 A/eq/Northamptonshire/1/13 EIV strain, 158 days (around 5.2 months) after V2 and their clinical signs and virus shedding were monitored. EI serology was measured by single radial haemolysis (SRH) and haemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and hen's egg titration) were compared with controls. All vaccinates had detectable

Indexed as

duration of immunityequine influenzahorsevaccination

Identifiers

PMID30004410
PMCPMC6161116
OpenAlexW2810877315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.